Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
Clinical trial NCT03185819 · COMPLETED
Trial details
- NCT number
- NCT03185819
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-05
- Primary completion
- 2023-03-31
- Enrollment
- 147
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.